Brief: Galera Announces Results From Phase 1 Stage Of Greco-1 Trial Of Rucosopasem With SBRT For NSCLC

Galera Therapeutics

29/06/2022 12:32

June 29 (Reuters) - Galera Therapeutics Inc  GRTX.O :
    * GALERA ANNOUNCES RESULTS FROM PHASE 1 STAGE OF GRECO-1
TRIAL OF
RUCOSOPASEM WITH SBRT FOR NSCLC
    * GALERA THERAPEUTICS INC - RUCOSOPASEM WAS SAFE AND WELL
TOLERATED
    * GALERA THERAPEUTICS INC - EARLY INDICATIONS OF ANTI-CANCER
ACTIVITY AND PULMONARY FUNCTION PRESERVATION
    * GALERA THERAPEUTICS INC - ENROLLMENT ONGOING IN
RANDOMIZED,
DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 2 STAGE OF THIS TRIAL
    * GALERA THERAPEUTICS INC - COMPLETION OF ENROLLMENT FOR
PHASE 2
STAGE OF TRIAL ANTICIPATED IN SECOND HALF OF 2023
    * GALERA THERAPEUTICS INC - IN-FIELD PARTIAL RESPONSES OR
STABLE
DISEASE WERE SEEN IN SIX OF SEVEN PATIENTS AT SIX MONTHS
FOLLOW-UP
    * GALERA THERAPEUTICS INC - ALL SEVEN PATIENTS ARE ALIVE
THROUGH A
MINIMUM OF NINE MONTHS OF FOLLOW-UP
    * GALERA THERAPEUTICS INC - EARLY EVIDENCE OF PROTECTION OF
PULMONARY FUNCTION WAS OBSERVED COMPARED TO LITERATURE
    * GALERA THERAPEUTICS INC - NO GRADE 2-4 (RTOG SCALE)
DECLINES IN
DLCO1 WERE SEEN IN ANY OF SEVEN PATIENTS RECEIVING RUCOSOPASEM

Source text for Eikon:  ID:nGNX1M50vQ 
Further company coverage:  GRTX.O